Nathan Trookman, MD
Dermatology · Colorado Springs, CONPI 1679669568
Payments from drug & device makers
What this record shows
AbbVie accounts for 64.2% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2024 at $6,264 and has fallen 83.8% since, to $1,017 in 2025. Among dermatology clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 206 payments — averaging $52.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$7K
- Galderma Laboratories, L.p.$874
- Almirall LLC$316
- UCB, Inc.$285
- Novartis$264
- Regeneron Healthcare Solutions, Inc.$244
- plus $2K from 21 others
Across 12 payments — averaging $1020.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$12K
What the payments were for
- Speaking & faculty fees$5,00046%
- Food & beverage$5,88354%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 54 | $6,992 |
| Galderma Laboratories, L.p. | 46 | $874 |
| Almirall LLC | 4 | $316 |
| UCB, Inc. | 7 | $285 |
| Novartis | 10 | $264 |
| Regeneron Healthcare Solutions, Inc. | 6 | $244 |
| Incyte Corporation | 7 | $225 |
| Sun Pharmaceutical Industries Inc. | 11 | $216 |
| Johnson & Johnson | 7 | $211 |
| Amgen | 5 | $204 |
| Sanofi | 8 | $190 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 5 | $141 |
| Genentech USA, Inc. | 2 | $125 |
| Lilly USA, LLC | 8 | $123 |
| Pfizer | 7 | $114 |
| Arcutis Biotherapeutics, Inc. | 3 | $67 |
| Merz North America, Inc. | 2 | $44 |
| Journey Medical Corporation | 3 | $42 |
| Solta Medical, A Division Of Bausch Health US, LLC | 2 | $42 |
| Bristol Myers Squibb | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 1 | $28 |
| LEO Pharma Inc. | 1 | $25 |
| Boehringer Ingelheim | 1 | $22 |
| EPI Health, LLC | 1 | $18 |
| Dermira, Inc. | 1 | $15 |
| Aclaris Therapeutics, Inc. | 1 | $12 |
| Prugen, Inc. Pharmaceuticals | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,883 in reported general payments places this provider in the 90th percentile of 280 dermatology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cosentyx Sensoready (2 Pens)Secukinumab | 13 | $97,106 |
| RinvoqUpadacitinib | 15 | $96,082 |
| Dutasteride | 142 | $5,408 |
| Clobetasol Propionate | 129 | $4,540 |
| Triamcinolone Acetonide | 182 | $2,810 |
| Minoxidil | 159 | $2,784 |
| Minocycline Hcl | 76 | $2,394 |
| Mometasone Furoate | 97 | $1,839 |
| Metronidazole | 34 | $1,729 |
| Desonide | 41 | $1,402 |
| ValacyclovirValacyclovir Hcl | 74 | $1,289 |
| Fluocinolone Acetonide | 17 | $625 |
| Fluocinolone AcetonideFluocinolone/Shower Cap | 13 | $613 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 12 | $607 |
| Ketoconazole | 20 | $527 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $6,992 | $96,08215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 280 dermatology providers in Colorado.
Other dermatology in Colorado Springs
- Victoria MossColorado Springs$473K
- Kathleen ElmerColorado Springs$10K
- Elizabeth PiantanidaColorado Springs$8K
- Marcjonathan SerotaLittleton$3.2M
- Ammon LarsenLoveland$620K
- Sheila BoyleWestminster$240K
- Mary Margaret KoberGlenwood Springs$202K
- Cathy KogerBoulder$182K
- Mona SadeghpourLone Tree$159K
- David NorrisAurora$156K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.